A Multicenter, Randomized, Open-label Phase II Clinical Study on the Efficacy and Safety of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy Subjects.
Latest Information Update: 25 Apr 2025
At a glance
- Drugs HRS-1893 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 22 Apr 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 26 Jul 2024 New trial record